These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 24939535)

  • 1. [HIV-1 cell-to-cell transmission and broadly neutralizing antibodies].
    Malbec M; Mouquet H; Schwartz O
    Med Sci (Paris); 2014 May; 30(5):508-10. PubMed ID: 24939535
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
    van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
    AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly neutralizing antibodies and the promise of universal vaccines: where are we now?
    Hefferon KL
    Immunotherapy; 2014; 6(1):51-7. PubMed ID: 24341884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.
    Caskey M; Klein F; Nussenzweig MC
    N Engl J Med; 2016 Nov; 375(21):2019-2021. PubMed ID: 27959740
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV neutralizing antibodies: clinical correlates and implications for vaccines.
    Doria-Rose NA
    J Infect Dis; 2010 Apr; 201(7):981-3. PubMed ID: 20170372
    [No Abstract]   [Full Text] [Related]  

  • 6. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.
    Euler Z; van Gils MJ; Bunnik EM; Phung P; Schweighardt B; Wrin T; Schuitemaker H
    J Infect Dis; 2010 Apr; 201(7):1045-53. PubMed ID: 20170371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 at the immunological and T-lymphocytic virological synapse.
    Haller C; Fackler OT
    Biol Chem; 2008 Oct; 389(10):1253-60. PubMed ID: 18713012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV superinfection in women may boost immune response.
    Rose S
    Expert Rev Anti Infect Ther; 2012 May; 10(5):525. PubMed ID: 22702314
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune Interventions to Eliminate the HIV Reservoir.
    Hsu DC; Ananworanich J
    Curr Top Microbiol Immunol; 2018; 417():181-210. PubMed ID: 29071472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HIV-1 Entry Process: A Stoichiometric View.
    Brandenberg OF; Magnus C; Regoes RR; Trkola A
    Trends Microbiol; 2015 Dec; 23(12):763-774. PubMed ID: 26541228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mouse model for HIV-1 entry.
    Pietzsch J; Gruell H; Bournazos S; Donovan BM; Klein F; Diskin R; Seaman MS; Bjorkman PJ; Ravetch JV; Ploss A; Nussenzweig MC
    Proc Natl Acad Sci U S A; 2012 Sep; 109(39):15859-64. PubMed ID: 23019371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies.
    Abela IA; Berlinger L; Schanz M; Reynell L; Günthard HF; Rusert P; Trkola A
    PLoS Pathog; 2012; 8(4):e1002634. PubMed ID: 22496655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection.
    Stiegler G; Katinger H
    J Antimicrob Chemother; 2003 Apr; 51(4):757-9. PubMed ID: 12654737
    [No Abstract]   [Full Text] [Related]  

  • 14. Macrophage internal HIV-1 is protected from neutralizing antibodies.
    Koppensteiner H; Banning C; Schneider C; Hohenberg H; Schindler M
    J Virol; 2012 Mar; 86(5):2826-36. PubMed ID: 22205742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies.
    Alving CR; Beck Z; Karasavva N; Matyas GR; Rao M
    Mol Membr Biol; 2006; 23(6):453-65. PubMed ID: 17127618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly neutralizing antibodies: An approach to control HIV-1 infection.
    Yaseen MM; Yaseen MM; Alqudah MA
    Int Rev Immunol; 2017 Jan; 36(1):31-40. PubMed ID: 27739924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
    Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
    AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for HIV Infection.
    Weiss RA
    N Engl J Med; 2014 Jan; 370(4):379-80. PubMed ID: 24450898
    [No Abstract]   [Full Text] [Related]  

  • 20. Remodeling of dynamic structures of HIV-1 envelope proteins leads to synthetic antigen molecules inducing neutralizing antibodies.
    Nakahara T; Nomura W; Ohba K; Ohya A; Tanaka T; Hashimoto C; Narumi T; Murakami T; Yamamoto N; Tamamura H
    Bioconjug Chem; 2010 Apr; 21(4):709-14. PubMed ID: 20359196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.